Poly Medicure Limited
NSE: POLYMEDINE205C01021·HealthcareSmallcap 250·www.polymedicure.com ↗·Mcap ₹17,504 Cr·Listed 2011
₹1,724.40▲ ₹8.40  (0.49%)
52W: ₹1,182 – ₹2,094 · Vol: 52.5K shares · Close 25 Sept
Set Alert

Your Screens

the ones you keep on the screener

Ready-made Screens It Passes

each filter against POLYMED's own figure
POLYMED passes none of the ready-made screens today.

One or two filters away

which filter, and by how much
476 companies pass it today · see them →
✓
revenue growth at least 15%18.3%
✗
profit growth at least 15%-12.5%
92 companies pass it today · see them →
✓
made a profit over the last four quarters₹313 Cr
✗
dividend yield at least 3%0.2%
249 companies pass it today · see them →
✓
made a profit over the last four quarters₹313 Cr
✗
P/E at most 1555.9
✓
market cap at least ₹1,000 Cr₹17,504 Cr
262 companies pass it today · see them →
✓
made a profit over the last four quarters₹313 Cr
✗
P/B at most 15.6
123 companies pass it today · see them →
✗
within 10% of its 52-week high61% of the way up
✓
market cap at least ₹5,000 Cr₹17,504 Cr
135 companies pass it today · see them →
✗
within 10% of its 52-week low61% of the way up
✓
market cap at least ₹5,000 Cr₹17,504 Cr
59 companies pass it today · see them →
✗
top 100 by market cap#406
✓
made a profit over the last four quarters₹313 Cr
✗
ROE at least 15%10.1%

3 other ready-made screens it misses on every filter or on more than two. All screens →

POLYMED Figuresrebuilt 26 Sept
Market cap₹17,504 Cr
Rank by market cap#406
P/E55.9
P/B5.6
ROE10.1%
Debt to equity0.11
Revenue growth18.3%
Profit growth-12.5%
Net margin15.7%
Dividend yield0.2%
Place in its 52-week range61% of the way up
Below its 52-week high16.4%
Daily turnover₹25 Cr

The last four quarters of filings, consolidated where the company files it, and our end-of-day closes. These are the numbers every filter on this page is held against.

Write Your Own
A screen is a line of English: “debt free with roe above 20%”. Keep one, and it is run again every night; this page then shows whether POLYMED passes it.
Open the screener →